LGVN (Longeveron) GF Value : $19.71 (As of Mar. 24, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Longeveron GF Value?

As of today (2025-03-24), Longeveron's share price is $1.86. Longeveron's GF Value is $19.71. Therefore, Longeveron's Price-to-GF-Value for today is 0.09. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Longeveron is Possible Value Trap, Think Twice.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Longeveron (NAS:LGVN) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Longeveron's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.86	/	19.71
	=	0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longeveron GF Value Related Terms

Thank you for viewing the detailed overview of Longeveron's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Longeveron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136

Website

https://www.longeveron.com

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Executives

Khoso Baluch	director	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Hashad Mohamed Wa'el Ahmed	officer: Chief Executive Officer	SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare	director, officer: Chief Scientific Officer	C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Cathy Ross	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Jeffrey Pfeffer	director
Lisa Locklear	officer: Chief Financial Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova	officer: Chief Medical Officer	1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo	officer: CFO and Treasurer	1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Kwan-hong Christopher Min	officer: Chief Medical Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green	officer: CEO	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr	officer: General Counsel, Secretary	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer	director, 10 percent owner	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136